{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01218464",
      "OrgStudyIdInfo": {
        "OrgStudyId": "Beijing302-003"
      },
      "Organization": {
        "OrgFullName": "Beijing 302 Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure",
      "OfficialTitle": "Phase Ⅰ/Ⅱ Study of Human Umbilical Cord Derived Mesenchymal Stem Cells (UC-MSCs) for Treatment of Liver Failure"
    },
    "StatusModule": {
      "StatusVerifiedDate": "May 2013",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2009"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "March 2014",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 2014",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "October 8, 2010",
      "StudyFirstSubmitQCDate": "October 8, 2010",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 11, 2010",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "May 30, 2013",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "May 31, 2013",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Fu-Sheng Wang",
        "ResponsiblePartyInvestigatorTitle": "Director",
        "ResponsiblePartyInvestigatorAffiliation": "Beijing 302 Hospital"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Beijing 302 Hospital",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Liver failure (LF) is a dramatic clinical syndrome with massive necrosis of liver cells. and liver transplantation is the only available therapeutic option for patients suffering with this condition. However, lack of donors, surgical complications, rejection, and high cost are serious problems. Previous study showed that bone marrow derived mesenchymal stem cells (BM-MSCs) replace hepatocytes in injured liver, and effectively rescue experimental liver failure and contribute to liver regeneration. In this study, the patients with LF will undergo administration of human umbilical cord mesenchymal stem cells (UC-MSCs) via peripheral vein transfusion to evaluate the safty and efficacy of UC-MSCs treatment for these patients.",
      "DetailedDescription": "Liver failure (LF) is a severe life-threatening condition, and is a dramatic clinical syndrome with massive necrosis of liver cells, and liver transplantation is the only available therapeutic option for patients suffering with this condition. However, lack of donors, surgical complications, rejection, and high cost are serious problems. Since current therapeutic options for LF that is usually with extremely poor prognosis are still limited, recent studies indicate that mesenchymal stem cells (MSCs), due to their function in immune modulation and liver-damage repair, are of great therapeutic potential for this disease. Previous study showed that bone marrow derived mesenchymal stem cells (BM-MSCs) replace hepatocytes in injured liver, and effectively rescue experimental liver failure and contribute to liver regeneration.The purpose of this study is to investigate the safety and initial efficacy of human umbilical cord MSC (UC-MSCs) treatment for patients with LF. In this study, MSCs were isolated from umbilical cord and generated in appropriate growth medium. 50 LF patients with LF received i.v. transfusion of 0.5-1.0×106 cells/kg of MSCs as the treated group and other 20 LF patients with LF were transfused with placebo without MSCs as control group. All 70 of them received the routine management for liver failure. During the 2-year follow up, the evaluation of safty and efficacy will be undergone to help to establish innovative cell-based therapies for the treatment of diseases."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Liver Failure",
          "Mesenchymal Stem Cells"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Liver Failure",
          "Mesenchymal Stem Cells",
          "Model for End-Stage Liver Disease",
          "Ascite",
          "Serum Albumin"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Double",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "70",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Conventional plus MSC treatment",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants will receive conventional treatment plus a dose of MSC from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Conventional plus MSC treatment"
              ]
            }
          },
          {
            "ArmGroupLabel": "Conventional plus pacebo treatment",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Conventional plus pacebo treatment"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Conventional plus MSC treatment",
            "InterventionDescription": "Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5*10E6 MSC/kg body for 12 weeks.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Conventional plus MSC treatment"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Conventional plus pacebo treatment",
            "InterventionDescription": "Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Conventional plus pacebo treatment"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "The levels of serum Total Protein and Albumin",
            "PrimaryOutcomeTimeFrame": "2 years after treatment"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "The levels of serum Total Bilirubin and Direct Bilirubin",
            "SecondaryOutcomeTimeFrame": "2 years after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "The levels of serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Cholinesterase (CHE)",
            "SecondaryOutcomeTimeFrame": "2 years after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "The level of alpha-fetoprotein (AFP)",
            "SecondaryOutcomeTimeFrame": "2 years after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "The content of ascites",
            "SecondaryOutcomeTimeFrame": "2 years after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Survival rate and time",
            "SecondaryOutcomeTimeFrame": "2 years after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Body temperature, tetter and allergy",
            "SecondaryOutcomeTimeFrame": "Between 0 to 24 hours after UC-MSCs transfusion"
          },
          {
            "SecondaryOutcomeMeasure": "The levels of Prothrombin Activity (PA) and Prothrombin Time (PT)",
            "SecondaryOutcomeTimeFrame": "2 years after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "The score for Model for End-Stage Liver Disease",
            "SecondaryOutcomeTimeFrame": "2 years after treatment"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAged 18-70 years\nLiver failure\nNegative pregnancy test (female patients in fertile age)\nWritten consent\n\nExclusion Criteria:\n\nHepatocellular carcinoma or other malignancies\nSevere problems in other vital organs(e.g.the heart,renal or lungs)\nPregnant or lactating women\nSevere bacteria infection\nAnticipated with difficulty of follow-up observation\nOther candidates who are judged to be not applicable to this study by doctors",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Fu-Sheng Wang, Professor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86-10-63879735",
            "CentralContactPhoneExt": "2015.12",
            "CentralContactEMail": "fswang@public.bta.net.cn"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Fu-Sheng Wang, Professor",
            "OverallOfficialAffiliation": "Beijing 302 Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Beijing 302 Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Beijing",
            "LocationState": "Beijing",
            "LocationZip": "100039",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Ming Shi, Professor",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "86-10-63879735",
                  "LocationContactPhoneExt": "2015.12",
                  "LocationContactEMail": "shiming302@sina.com"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "18455168",
            "ReferenceType": "background",
            "ReferenceCitation": "Kuo TK, Hung SP, Chuang CH, Chen CT, Shih YR, Fang SC, Yang VW, Lee OK. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008 Jun;134(7):2111-21, 2121.e1-3. doi: 10.1053/j.gastro.2008.03.015. Epub 2008 Mar 12."
          },
          {
            "ReferencePMID": "18243183",
            "ReferenceType": "background",
            "ReferenceCitation": "Campard D, Lysy PA, Najimi M, Sokal EM. Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology. 2008 Mar;134(3):833-48. doi: 10.1053/j.gastro.2007.12.024. Epub 2007 Dec 23."
          },
          {
            "ReferencePMID": "16778155",
            "ReferenceType": "background",
            "ReferenceCitation": "Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K, Yamasaki T, Fujii Y, Okita K, Sakaida I. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006 Oct;24(10):2292-8. Epub 2006 Jun 15."
          },
          {
            "ReferencePMID": "17903050",
            "ReferenceType": "result",
            "ReferenceCitation": "Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, Baharvand H, Ghavamzadeh A, Malekzadeh R. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 2007 Oct;10(4):459-66. Erratum in: Arch Iran Med. 2008 Jan;11(1):135."
          },
          {
            "ReferencePMID": "19455046",
            "ReferenceType": "result",
            "ReferenceCitation": "Kharaziha P, Hellström PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost M, Zali MR, Soleimani M. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009 Oct;21(10):1199-205. doi: 10.1097/MEG.0b013e32832a1f6c."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000017093",
            "ConditionMeshTerm": "Liver Failure"
          },
          {
            "ConditionMeshId": "D000048550",
            "ConditionMeshTerm": "Hepatic Insufficiency"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000008107",
            "ConditionAncestorTerm": "Liver Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10259",
            "ConditionBrowseLeafName": "Liver Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M28321",
            "ConditionBrowseLeafName": "End Stage Liver Disease",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18567",
            "ConditionBrowseLeafName": "Liver Failure",
            "ConditionBrowseLeafAsFound": "Liver Failure",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M25123",
            "ConditionBrowseLeafName": "Hepatic Insufficiency",
            "ConditionBrowseLeafAsFound": "Liver Failure",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M10262",
            "InterventionBrowseLeafName": "Liver Extracts",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Hemat",
            "InterventionBrowseBranchName": "Hematinics"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}